Bainamin Injection

Adult dosage

Generally, for adults, 1-1.5 g per kg of body weight of total amino acids is administered intravenously as a maximum dose. The administration rate should ideally be such that approximately 10 g of total amino acids is infused over 60 minutes, with a principle of administering 80-130 drops per minute. The maximum daily dose is 100 g of D-sorbitol.

Children's dosage

Dosing and infusion rates should be adjusted for children.

This medication should be used strictly according to a physician's instructions. It should not be used in patients with hepatic coma or those at risk of hepatic coma, patients with severe renal impairment, or patients with certain metabolic disorders. Additionally, it should be avoided in patients with heart failure, pulmonary edema, or conditions where there is very little urine output, such as oliguria or anuria. Some of the ingredients in this medication may pose risks to patients with specific genetic disorders or a history of heart disease, so caution is needed. Particularly, in patients with liver or kidney dysfunction, hyperkalemia, and those who may experience certain allergic reactions, it should be administered carefully. This medication can cause serious allergic reactions, such as anaphylaxis or asthma attacks, so asthma patients or those with allergic tendencies should be cautious. During use, rare hypersensitivity reactions such as skin rashes may occur, as well as digestive symptoms such as nausea or vomiting. Also, cardiovascular symptoms or hypotension may appear, and with excessive doses, metabolic acidosis may occur, so caution should be exercised. The magnesium ions contained in this medication may cause peripheral vasodilation and could lead to metabolic complications or deterioration of liver and kidney function, thus observing the condition closely is necessary. With large doses, particular attention should be paid to maintaining electrolyte balance, and patients with renal, pulmonary, or cardiac diseases should avoid excessive fluid overload. Diabetics should regularly monitor their blood sugar levels. There may be interactions when combined with other medications, particularly when using tetracycline antibiotics or calcium salts. In pregnant women, safety has not been established, and it should only be administered if the therapeutic benefits outweigh the risks. In children, liver function may be immature, so concentrations should be kept low, and blood ammonia levels should be regularly monitored. Elderly patients should have their administration rate slowed and doses adjusted, considering diminished bodily functions. When administering, electrolyte balance must be maintained, and it should be slowly administered intravenously at body temperature. Preparation and management should be done under aseptic conditions, and degraded solutions should not be used. During storage, keep the package unopened and promptly discard any solution showing discoloration or leakage. This medication should be used accurately according to the markings on the container.

Serious side effects

• Difficulty breathing, respiratory arrest, shock, bronchoconstriction, headache, and coma may occur.
• It should not be administered to patients with myocardial infarction or those with a history of it.
• Severe allergic reactions, such as anaphylaxis and asthma attacks, may occur.

Mild side effects

• Rarely, hypersensitivity symptoms such as rashes may occur.
• Digestive symptoms such as nausea and vomiting may sometimes occur.
• Cardiovascular symptoms such as chest discomfort, palpitations, tachycardia, and hypotension may occur.
• Chills, fever, headache, and urinary colic may occur.
• Peripheral vasodilation may occur.
• Metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, osmotic diuresis, and dehydration.

This medication should be stored in a sealed container to prevent air or moisture from entering. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius. Keeping it this way will help maintain the drug's effectiveness.

Appearance

A yellow transparent injection solution in a colorless transparent bottle or plastic container with a rubber stopper for infusion.

Package unit

200mL/bottle, 250mL/bottle, 400mL/bottle, 100mL/bag